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Vasoactive prostanoids may be involved in persis-
tent pulmonary hypertension (PPH) in infants
with a congenital diaphragmatic hernia (CDH).
We hypothesized that increased levels of prosta-
noids in bronchoalveolar lavage (BAL) ￿ uid
would predict clinical outcome. We measured the
concentrations of 6-keto-prostaglandin F1a (6-
keto-PGF1a), thromboxane B2 (TxB2), protein,
albumin, total cell count, and elastase-a1-protei-
nase-inhibitor complex in BAL ￿ uid of 18 CDH
patients and of 13 control subjects without PPH.
We found different concentrations of prostanoids
in BAL ￿ uid of CDH patients with PPH: infants
with a poor prognosis had either high levels of
both 6-keto-PGF1a and TxB2 compared to controls,
or high levels of 6-keto-PGF1a only. TxB2 levels
showed a large variability in all CDH patients
irrespective of outcome. We conclude that prosta-
noid levels in BAL ￿ uid do not predict clinical
outcome in CDHpatients.
Key words: Arti￿cial ventilation, Extracorporeal mem-
brane oxygenation, Congenital diaphragmatic hernia,
Persistent pulmonary hypertension, Prostacyclin,
Thromboxane
Introduction
The high mortality of morbidity in children with
congenital diaphragmatic hernia (CDH) is lar-
gely determined by the severity of lung hypo-
plasia and persistent pulmonary hypertension
(PPH).1 Despite improved neonatal intensive
care, the overall survival rate still does not
exceed 60%.2 Several attempts have been made
to predict mortality in these patients. A recent
study showed that data reported to the Extra-
corporeal Life Support Organization Registry of
more than 1000 CDH patients treated with
extracorporeal membrane oxygenation (ECMO)
did not allow discrimination of non-survivors
from survivors.3
In the lung, arachidonic acid metabolites
regulate the bronchial and vascular tone, and
are involved in in￿ammatory processes.4 In-
creased levels of eicosanoids have been re-
ported in plasma and in bronchoalveolar lavage
(BAL) ￿uid of children with PPH who were
treated with conventional ventilation or with
ECMO.5- 8 Increased plasma levels of the stable
metabolites of the pulmonary broncho-, and
vasoconstrictor thromboxane A2 (TxA2) and the
pulmonary vasodilator prostacyclin (PGI2),
TxB2, and 6-keto-PGF1a have been observed in
CDH patients during episodes of hypoxemia,9
and in the immediate postoperative period. 10- 12
BAL has been used to evaluate different aspects
of in￿ammatory responses, such as the number
of neutrophilic granulocytes and macrophages,
albumin, elastase, and a1-proteinase inhibitor
activity in ventilated preterm infants with re-
spiratory distress syndrome who were likely to
develop chronic lung disease. 13- 15 We hypothe-
sized that in CDH patents, involvement of
vasoactive prostanoids in the pathogenesis of
PPHwould be re￿ected by increased prostanoid
levels in BAL ￿uid, and that these concentra-
tions might have a predictive value with respect
to clinical outcome.
The aim of the present study was to measure
the concentrations of 6-keto-PGF1a, TxB2, and
various in￿ammation markers in BAL ￿uid of
CDH patients who were treated either with
conventional ventilation or with ECMO and to
evaluate the prostanoid levels in relation to
outcome. The levels of different parameters in
BAL￿uid were compared with those of controls
without PPH who had similar gestational age
and birth weight.
Patients and Methods
Patients
The study was performed in our Paediatric
Surgical Intensive Care Unit between December
Mediators of In¯ ammation ´ Vol 6 ´ 1997 2171993 and January 1996. A group of 18 CDH
patients were studied; 13 children underwent
conventional ventilation (referred to as the
CDH-CV group), and ￿ve children were treated
with venoarterial ECMO (referred to as the
CDH-ECMO group) using standardized treat-
ment protocols. 16- 18 Four CDH patients had
been diagnosed prenatally. T en patients in the
CDH-CV group and all ￿ve ECMO patients
suffered from respiratory insuf￿ciency within 6
hours of birth; the other three patients were
respiratory insuf￿cient after 10 hours, 36 hours,
and 28 days, respectively. Operative repair by
an abdominal approach was performed in 11
conventionally ventilated children and in three
ECMO patients after preoperative clinical stabi-
lization;16 four of the ￿ve patients who died had
not been operated on. All 18 patients routinely
received antimicrobial prophylaxis. They under-
went echocardiography on admission: right-to-
left shunting was diagnosed in six children of
the CDH-CV group and in all CDH-ECMO pa-
tients.12 Clinical evidence for right-to-left shunt-
ing was obtained by preductal and postductal
transcutaneous O2-saturation differences of
. 10% in ￿ve CV-patients and in all ECMO
patients.
For CDHpatients in our institution the entry
criteria for ECMO were: gestational age of at
least 34 weeks; birth weight at least
2000 grams; arti￿cial ventilation for less than
7 days; alveolar±arterial oxygen difference
(A-aDO2). 80 kPa (600 torr); maximal PaO2 at
least 10 kPa. During ECMO ventilatory settings
were usually reduced to PIP 12±16 cm H 2O,
PEEP 5±6 cm H 2O, rate 10±15/min, and FIO2
0.25±0.3.
Thirteen other children without pulmonary
abnormalities, who were mainly ventilated peri-
operatively at a median age of 2.5 days (range
1±8 days), served as age-matched controls. They
were selected for the best possible match for
age, gestational age and birth weight. They all
received antimicrobial therapy. Echocardiogra-
phy was performed in ￿ve controls to exclude
structural cardiac anomalies; none of these had
evidence of right-to-left shunting.
In all 31 patients cultures of tracheal aspirates
were routinely performed every 3 days. The
study was conducted according to the princi-
ples established in the Declaration of Helsinki
and approved by the Medical Ethical Committee
of our hospital.
Study design
Of each patient the following data were re-
corded: gestational age, birth weight, diagnosis,
survival, age at admission and at discharge or
death, age at start of respiratory insuf￿ciency,
duration of ECMO and/or arti￿cial ventilation,
and duration of supplemental O2 therapy. Out-
come parameters were: mortality and O2-depen-
dency at 28 days, as a criterion for chronic lung
disease.19
Bronchoalveolar lavage was performed on day
1, day 3 and day 7 and once every week
thereafter as long as endotracheal intubation
was continued and the child remained in our
Intensive Care Unit. However, an unstable
clinical condition was a reason to modify this
schedule.
The following data were recorded at each
BAL procedure: clinical events such as surgery,
mean airway pressure (MAP), oxygenation in-
dex (OI), and AaDO2.16 Arterial blood gases
were obtained within 6 hours of the time of
BAL.
BAL procedure
The procedure was performed directly after
routine endotracheal suctioning by the nursing
staff using a technique described by Grigg et
al.20 The patient’s head turned left, a 5 Fr open-
ended catheter (outer diameter 1.7 mm; Sher-
wood Medical, Petit Rechain, Belgium) was
passed down the endotracheal tube and placed
in wedge position. Warmed 0.9% NaCl was
instilled in two aliquots of 1 ml/kg each. Gentle
manual suctioning with a 20-ml syringe was
directly performed after each aliquot. In most
cases the ventilatory circuit was not broken.
The whole procedure always took less than
1 min. The recovered ￿uid was immediately
processed; 20 ml was aspirated for cell counting,
the remaining ￿uid was centrifuged at 900 3 g.
The supernatant was frozen at - 808 C, the cells
were resuspended in 0.9%NaCl and processed
for cytocentrifugation.
Measurements in BAL ¯ uid
BAL ￿uid was diluted in Tu ¨rk stain (1:10) for
cell counting in a Bu ¨rker-haemocytometer. Dif-
ferential cell counts were carried out on cyto-
spin slide preparations with May±Gruenwald±
Giemsa stain. In the supernatant 6-keto-PGF1a
and TxB2 were measured by radioimmunoassay
as described previously, using standard prosta-
glandins from Sigma Co. (St Louis, MO, USA)
and antibodies from Advanced Magnetics Inc.
(Cambridge, MA, USA).21 Elastase-a1-proteinase
inhibitor-complex (E-a1-PI) was determined
using a commercially available kit (PMN Elas-
tase; Merck Immunoassay 11332; Merck, Ger-
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pitation using N-antiserum against human albu-
min (Behring OSAL 14/15; Behring, France).
Human albumin (20% ) (CLB, Amsterdam, The
Netherlands) was used to obtain standard
curves. Total protein was measured as described
by Lowry,22 standard curves were obtained
using Preciset 6 g/100 ml (Boehringer 125610;
Boehringer, Germany).
Data analysis
Data were expressed as median (range) unless
stated otherwise. Because of a low yield of BAL
￿uid, not all measurements could be performed
for all samples, which resulted in incomplete
data. Ventilatory parameters were compared
between groups using the non-parametric
Mann±Whitney U-test. Two tailed Spearman’s
rank correlation coef￿cient was used to study
the relationship between different parameters
in BAL ￿uid and ventilatory parameters during
the ￿rst 3 days of treatment. In those cases
where more than one BAL procedure was
performed within the ￿rst 3 days, the average
value of each parameter was used for calcula-
tion of the correlation coef￿cient. Statistical
signi￿cance was assumed at the 5%level.
Results
Patient characteristics
The characteristics of all patients are sum-
marized in T able 1. Ventilated controls had
the following diagnoses: meconium peritonitis
(n= 4), oesophageal atresia (n= 4), M. Hirsch-
sprung, necrotizing enterocolitis, vesical exstro-
phy, hiatus hernia with Ehlers±Danlos syn-
drome, wet lung (each n = 1). None of the con-
trols showed evidence of PPHat any time. Ten
CDH-CV patients had left-sided CDH and three
had a right-sided defect. Six CDH-CV patients
had PPH: two of those, who never met the
ECMO entry criteria as a result of a persistently
low PaO2, died during the ￿rst hours after birth.
Four CDH-CV patients were O2-dependent at
the age of 28 days (one patient without
documented PPH). Of the CDH-ECMO patients,
who all had documented PPH, one had a
bilateral diaphragmatic defect, the other four
had left-sided CDH. Two survivors were oper-
ated on while undergoing ECMO, and they were
both O2-dependent at 28 days. The other three
ECMO patients died from recurrent episodes of
therapy-resistant pulmonary hypertension 5±11
days after decanulation; one of these patients
was operated on during ECMO on day 20. In
these three patients BAL was not performed
after decanulation because their clinical condi-
tion was unstable and deteriorated rapidly.
In only one CDH-CV patient there was evi-
dence of PPHduring the BAL procedure; in all
other patients the pre-and postductal transcuta-
neous O2-saturation measurements were similar
during BAL.
Prostanoid concentrations in BAL
¯ uid of CDH patients
In all but one patient the prostanoid concentra-
tion in BAL ￿uid could be measured at least
Table 1. Characteristics of control subjects and CDH patients
Controls
n = 13 (13)a
CDH-CV
n = 13 (11)a
CDH-ECMO
n = 5 (2)a
Gestational age (weeks) 38 (36±41) 38.5 (34±41) 39 (34±42)
Birth weight (grams) 2710 (2350±3910) 3140 (1550±4340) 3000 (2380±3630)
Ventilation (days)b 3 (1±5) 10 (3±33) 42.5 (34±51)
Supplemental O2 (days)b 4 (1±12) 15 (3±47) 58 (35±81)f
O2-dependency at 28 days (n)b 0 4 2
Age at surgery CDH (days)b 4 (2±28c) 9.5 (6±13)
Age at start of ECMO (hours) ND 16 (6±42)
Duration of ECMO (days) ND 14 (6±25)
MAPd (day 1±2) 10 (7.7±25) 20 (4.6±62)e ND
(day 3±5) 8.9 (5.1±19) 17.7 (9.7±25)e ND
OId (day 1±2) 3.3 (2.3±13) 5.5 (1±250) ND
(day 3±5) 1.9 (1.1±4.8) 3.9 (2.6±13) ND
A-aDO2
d (day 1±2) 51 (81±230) 110 (17±638) ND
(day 3±5) 26 (18±81) 64 (24±235) ND
The median (range) values are shown for different patient characteristics. CDH-CV, conventionally ventilated CDH patients; CDH-ECMO,
ECMO-treated CDH patients. ND, not determined.
aThe total number of patients per group is shown, the number of survivors is shown in brackets.
bOnly data from survivors are shown.
cOne child was diagnosed at the age of 27 days, surgery was performed one day after diagnosis, no documented PPH.
dParameters calculated only at the time that BAL was performed, day 1±2: controls n= 6, CDH-CV n= 9; day 3±5: n= 6 for both groups.
eSigni® cantly different from controls, P , 0.05.
fOne child received additional O2-therapy 1 month later and is still O2-dependent at 32 months of age.
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Prostanoids in BAL￿uid of CDHpatientsonce; the sample volume of one CDH-CV pa-
tient, who died within several hours after birth,
was too small to measure prostanoid concentra-
tions. The concentrations of 6-keto-PGF1a and
TxB2 are shown in Figs 1 and 2, respectively
and in T able 2. Once CDH-CV patient with
evidence of PPH at the time of BAL who died
during the ￿rst day of life had a very high level
of 6-keto-PGF1a, the same was true for the initial
levels of two ECMO-treated CDH patients who
died later (Fig. 1A). In the group of CDH
survivors, only one patient who needed arti￿cial
ventilation for 4 weeks showed high levels of 6-
keto-PGF1a, whereas all other CDH-CV and
CDH-ECMO survivors had 6-keto-PGF1a levels
within the control ranges (Fig. 1B).
The concentrations of TxB2 varied irrespec-
tive of outcome (Fig. 2). Deterioration of the
clinical condition in one patient with PPHwho
developed sepsis on day 10, followed by throm-
bosis of the inferior vena cava, was not
re￿ected by an increase in prostanoids initially,
but by an increase in TxB2 a few days later; 6-
keto-PGF1a remained low.
Surprisingly, in two infants who died, one
CDH-CV patient and one CDH-ECMO patient,
FIG. 1. The concentrations of 6-keto-PGF1a in BAL ¯ uid of non-surviving CDH patients (A) and CDH survivors (B) are shown.
Conventionally ventilated patients, j , u ; ECMO-treated patients, n , m . Closed symbols represent a poor clinical outcome:
death (A) or O2-dependency at 28 days (B). Each measurement is indicated by an individual symbol, a line through the
symbols indicates that more BAL procedures were performed on one patient. The box represents the interquartile range
concentration of 6-keto-PGF1a during the ® rst 2 days of ventilation in 10 control patients without PPH.
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Table 2. Prostanoids in BAL ¯ uid of ventilated controls and CDH patients, and in CDH patients treated with ECMO
Controls-CVa,b CDH-CVa,c CDH-ECMOd
6-keto-PGF1a
e Day 1±2 73 (54±283) 114 (12±1089) 419 (61±455)
Day 3±5 72 (21±107) 64 (29±273) 73 (0±162)
Day 6±12 ND 120 (28±632) 134 (28±632)
TxB2
e Day 1±2 159 (91±252) 153 (54±563) 493 (360±626)
Day 3±5 109 (54±780) 153 (37±355) 159 (0±458)
Day 6±12 ND 467 (55±1172) 177 (55±285)
Values are indicated as median (range). Statistical analysis between the groups was not performed because of the missing data and the
different time points. ND, not determined.
aCV, conventional ventilation.
bn= 9±12 on Day 1±2 and n= 6 on day 3 (no lavage data were obtained in controls after Day 3).
cn= 7±9 on Day 1±2 and n = 5±7 on day 3±5.
dn= 3 on Day 1±2 and n= 5 on Day 3±5.
eConcentrations are expressed as pg per ml bronchoalveolar lavage ¯ uid.
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H. IJsselstijn et al.the ratio of 6-keto-PGF1a to TxB2 was high: 20
and 5.2 respectively. The median ratio of 6-keto-
PGF1a to TxB2 of the CDH-CV patients with
PPH did not differ from that of those without
PPH: 0.52 (0.14±20) versus 0.51 (0.02±2.5),
respectively; controls without PPH had a med-
ian ratio of 0.6 (0.14±1.6). In the ￿ve CDH-
ECMOpatients, who all had PPH, the ratio of 6-
keto-PGF1a to TxB2 was 0.7 (0.23±5.2).
The prostanoid concentrations did not corre-
late with any of the ventilatory parameters in
the conventionally ventilated groups.
In¯ ammatory markers in BAL ¯ uid
and correlation between different
parameters
Cultures of tracheal aspirates were negative in
all patients at the time of BAL. The total cell
count, the percentage of neutrophilic granulo-
cytes and macrophages, and the concentrations
of protein, albumin, and E-a1-PI in BAL are
shown in Table 3. During the ￿rst days the
median cell count and the levels of protein,
albumin, and E-a1-PI were high in the CDH-
ECMOgroup.
In CDH-CV patients a negative correlation
was found between the total cell count and
MAP , OI, and AaDO2 (r = - 0·06, - 0.58, and
- 0.56 respectively; P < 0·05; n = 11) and a
positive correlation between % neutrophilic
granulocytes and OI and AaDO2 (r = 0·49 and
0.57, respectively; P < 0·05; n= 12) during the
￿rst 3 days. In controls, albumin correlated
positively with MAP and OI (r = 0·68 and 0.69,
respectively; P < 0·05; n= 13 and 8, respec-
tively), and total protein correlated positively
with MAP (r = 0·63; P = 0·01; n= 13).
Discussion
We have found different concentrations of
prostanoids in BAL ￿uid of CDH patients with
PPH: in infants who died and in one infant
ventilated for more than 4 weeks either high
levels of 6-keto-PGF1a and TxB2 compared to
controls, or high levels of 6-keto-PGF1a only.
The ratio of 6-keto-PGF1a to TxB2 was high in
two CDH patients who died. Survivors with
evidence of PPHtreated with ECMO, and CDH
patients with O2-dependency at 28 days had
prostanoid levels which could not be discrimi-
nated from the levels of the other CDHpatients.
The levels of TxB2 were variable in all CDH
patients.
Increased levels of TxB2 and 6-keto-PGF1a
have been reported in plasma of neonates with
PPHwho were treated with conventional venti-
lation or with ECMO.6,7,9- 12 Dobyns et al.
FIG. 2. The concentrations of TxB2 in BAL ¯ uid of non-surviving CDH patients (A) and CDH survivors (B) are shown.
Conventionally ventilated patients, j , u ; ECMO-treated patients, n , m . Closed symbols represent a poor clinical outcome:
death (A) or O2-dependency at 28 days (B). Each measurement is indicated by an individual symbol, a line through the
symbols indicates that more BAL procedures were performed on one patient. The box represents the interquartile range
concentration of TxB2 during the ® rst 2 days of ventilation in 10 control patients without PPH.
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Prostanoids in BAL￿uid of CDHpatientsdescribed increased levels of TxB2, 6-keto-
PGF1a, PGD 2, PGE2, LTB4 and LTE4 in BAL ￿uid
of neonates with PPH.8 Prostanoid levels in
plasma and in BAL ￿uid were shown to de-
crease during the course of treatment in these
children7,8 and in one CDHpatient treated with
ECMO.11 Dobyns et al. found persisting high
levels of 6-keto-PGF1a and TxB2 in BAL ￿uid of
ECMO-treated children with PPH and a poor
outcome, whereas the prostanoid levels de-
creased rapidly in PPH patients with a good
outcome.8 Our ￿ndings of high levels of 6-keto-
PGF1a in infants who died are in accordance
with these ￿ndings, but the variable TxB2 levels
in all CDH patients ± irrespective their clinical
outcome ± contradict their observations.
To determine whether the high levels of
prostanoids in BAL ￿uid of some CDH patients
with PPHare a speci￿c feature of the abnormal
pulmonary vasculature in CDH, these levels
should be compared with prostanoid levels in
BAL ￿uid of children without CDH who need
ventilatory support to the same extent as the
most severely ill CDH patients. Our control
population consisted of infants who had mild
ventilatory requirements as re￿ected by the
ventilatory parameters. Therefore, these con-
trols did not allow for such comparison.
The relatively high and variable TxB2 levels in
the CDH patients, irrespective of the outcome,
suggest that the clinical situation in this group
of patients is not adequately re￿ected by the
TxB2 concentrations in BAL ￿uid. An earlier
study from our group showed a correlation
between plasma prostanoid levels and ventila-
tory parameters in CDHpatients.12 We were not
able to demonstrate such correlations in BAL in
our study. This may indicate that prostanoid
levels in the pulmonary vasculature are not
adequately re￿ected in BAL ￿uid, as has been
suggested by Abman et al.23 This was supported
by our ￿nding that in non-ventilated neonatal
rats with CDHthe concentration of TxB2 is 10-
fold higher in lung tissue than in BAL ￿uid.24
However, in these rat pups the ratio of 6-keto-
PGF1a to TxB2 was consistently increased in
lung tissue and in BAL ￿uid compared with
controls directly after birth, suggesting that this
parameter in BAL ￿uid may be representative
for the values in lung tissue.24 In the present
study a similar observation was made in two
CDH patients, but this was not a consistent
￿nding for all patients with a poor outcome.
The increased ratios of 6-keto-PGF1a to TxB2
suggest that the lungs compensate maximally
for the pulmonary vasoconstriction in CDH. It
is noteworthy that in neonatal rats with CDH
the presence of more pulmonary neuroendo-
Table 3. Total cell count, cell differentiation, albumin, total protein and elastase-a1-proteinase inhibitor complex (E-a1-PI) in
BAL ¯ uid of ventilated controls and CDH patients, and in CDH patients treated with ECMO
Controls-CVa,b CDH-CVa,c CDH-ECMOd
Cells (3 104)e Day 1±2 8.7 (1.7±90) 3.5 (1.7±63) 186 (28±227)
Day 3±5 13 (1.7±38) 10 (1.7±38) 43 (23±69)
Day 6±12 ND 12 (1.7±19) 30 (1.7±59)
Neutrophils (%) Day 1±2 70 (2±90) 73 (10±85) 79 (36±93)
Day 3±5 26 (11±86) 35 (3±72) 53 (33±86)
Day 6±12 ND 55 (17±76) 5 (0±26)
Macrophages (%) Day 1±2 22 (8±87) 12 (2±82) 14 (3±55)
Day 3±5 61 (8±84) 60 (13±92) 46 (9±63)
Day 6±12 ND 32 (20±50) 89 (74±99)
Albumin (mg)e Day 1±2 0.1 (0.005±0.31) 0.1 (0.04±1.11) 0.29 (0.02±1.5)
Day 3±5 0.09 (0.03±0.16) 0.05 (0.03±0.15) 0.11 (0.02±0.6)
Day 6±12 ND 0.06 (0.01±0.24) 0.02 (0.02±0.06)
Protein (mg)e Day 1±2 0.31 (0.02±1.67) 0.26 (0.12±2.03) 1.48 (0.09±2.9)
Day 3±5 0.25 (0.1±0.42) 0.16 (0.08±0.34) 0.41 (0.26±4.14)
Day 6±12 ND 0.13 (0.06±0.66) 0.12 (0.03±0.19)
E-a1-PI (mg)e Day 1±2 0.04 (0±1.95) 0.03 (0±0.63) 0.24 (0.004±0.9)
Day 3±5 0.04 (0±0.21) 0.03 (0±0.07) 0.07 (0±0.57)
Day 6±12 ND 0.02 (0±0.15) 0.02 (0.003±0.09)
Values are indicated as median (range). Statistical analysis between the groups was not performed because of the missing data and the
different time points. ND, not determined.
aCV, conventional ventilation.
bn= 9±12 on Day 1±2 and n= 6 on Day 3±5 (no lavage data were obtained in controls after Day 3).
cn= 7±9 on Day 1±2, n= 5±7 on Day 3±5, and n= 4±6 on Day 6±12.
dn= 3 on Day 1±2, n= 5 on Day 3±5, and n= 3±4 on Day 6±12.
eConcentrations are expressed per ml bronchoalveolar lavage ¯ uid.
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H. IJsselstijn et al.crine cells containing calcitonin gene-related
peptide, a peptide with a known vasodilatory
activity, has been reported. 25- 27 Furthermore, in
foetal lungs of rat pups with CDH, increased
mRNA levels of endothelin have been observed
recently (T . Okazaki, personal communication).
Interestingly, Bos et al. reported that in CDH
patients, all non-respondents to intravenous
prostacyclin therapy died.28 We speculate that
in some CDH patients the lungs already com-
pensate maximally for pulmonary vasoconstric-
tion and may be insensitive to therapeutic
interventions with pulmonary vasodilators, such
as prostacyclin and nitric oxide.
Increased cell counts, neutrophil numbers,
albumin, and elastase activity have been re-
ported in tracheal aspirates or BAL ￿uid of
prematurely born ventilated patients who devel-
oped chronic lung disease. 13- 15 in the present
study, concentrations of cells, protein, albumin,
and E-a1-PI complex in the BAL ￿uid of CDH-
ECMO patients were high, compared with con-
ventionally ventilated CDHpatients and controls
during the ￿rst days of treatment. T o our know-
ledge these parameters have not been reported
before in lung lavages of ECMO-treated neonates.
We assume that increased vascular permeability
with an in￿ux of cells is responsible and related
to lung injury and activation of the in￿ammatory
cascade before ECMO, or to neutrophil activa-
tion and protein in￿ux as part of the capillary
leakage syndrome in the initial phase of ECMO.29
Our study does not allow for de￿nite conclu-
sions regarding the question of whether the high
cell counts, and the high levels of protein,
albumin, and elastase-a1-PI-complex in ECMO-
treated CDH patients result from the disease
state or fromthe ECMOprocedure.
In conclusion, we found that in some CDH
patients with PPH high prostanoid concentra-
tions in BAL ￿uid were associated with a poor
outcome. These patients died within a few
hours of birth, or from recurrent episodes of
therapy-resistant pulmonary hypertension sev-
eral days after ECMO. The high levels of 6-
keto-PGF1a might have been induced by the
hypoxic vasoconstriction in these patients30 or
re￿ect an attempt by the lungs to compensate
maximally for the pulmonary vasoconstriction.
The variation in TxB2 concentrations may re-
￿ect lung injury and increased vascular per-
meability. This study illustrates the dif￿culties of
performing BAL procedures on a regular basis
in severely ill neonates and interpreting the
prostanoid levels in BAL ￿uid. Based on our
￿ndings we feel that the predictive value of
prostanoid levels in BAL ￿uid with respect to
outcome is questionable.
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